GenSight Biologics

GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel gene therapies for neurodegenerative diseases of the eye and central nervous system. Founded in 2012 and headquartered in Paris, France, the company's integrated development platform combines gene therapy with two proprietary technologies: Mitochondrial Targeting Sequence (MTS) and optogenetics. GenSight's lead programs target severe inherited retinal diseases, with the goal of preserving or restoring vision in patients with sight-threatening ophthalmic conditions. The company's product candidates are designed to be administered in a single intravitreal injection per eye, offering a potentially long-lasting cure with minimal patient burden. GenSight believes its technology platforms have broad applicability beyond ophthalmology, including potential applications in other central nervous system disorders. The company has progressed two product candidates into clinical trials and is investigating additional candidates across multiple neurodegenerative indications. GenSight Biologics is a publicly traded company listed on Euronext Paris.